Detalhe da pesquisa
1.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Neurology
; 92(23): e2661-e2673, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118245
2.
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study.
Sleep
; 31(7): 944-52, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18655317
3.
Pathophysiology, assessment and management of multiple sclerosis fatigue: an update.
Expert Rev Neurother
; 17(4): 373-379, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27728987
4.
Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
Mult Scler Relat Disord
; 8: 141-4, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27456890
5.
A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.
J Neurol Sci
; 364: 105-9, 2016 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27084226
6.
E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis.
J Neuroimmunol
; 165(1-2): 201-5, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15979159
7.
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.
Mult Scler Relat Disord
; 3(6): 732-4, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891553
8.
Opposite effects of interferon-ß on new B and T cell release from production sites in multiple sclerosis patients.
J Neuroimmunol
; 240-241: 147-50, 2011 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22078237